SCHEMBL424684

SCHEMBL424684

O=C(N1CCOC1)n1cnc(-c2ccccc2)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.45
TSHR P16473 2/20 0.45
LMNA P02545 2/20 0.45
RAB9A P51151 3/20 0.44
HSD17B10 Q99714 2/20 0.44
FAAH O00519 1/20 0.43
PTGS2 P35354 1/20 0.42
ACACB O00763 1/20 0.42
ACACA Q13085 1/20 0.42
SMN1; SMN2 Q16637 3/20 0.41
PLAUR Q03405 2/20 0.41
NPC1 O15118 2/20 0.41
TP53 P04637 1/20 0.41
HTT P42858 2/20 0.41
ADORA2A P29274 1/20 0.41
ADORA1 P30542 1/20 0.41
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
AKR1C3 P42330 1/20 0.40
EPHX1 P07099 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL426612 0.92 ALDH1A1 (0.51) ALDH1A1TSHRLMNARAB9AHSD17B10
SCHEMBL425475 0.77 TACR3 (0.53) ALDH1A1TSHRLMNARAB9AHSD17B10
SCHEMBL19293990 0.75 FAAH (0.47) ALDH1A1FAAHSMN1; SMN2ADORA2AADORA1
SCHEMBL425650 0.75 HPGD (0.53) ALDH1A1TSHRLMNARAB9AHSD17B10
SCHEMBL525635 0.75 CDK5 (0.47) ALDH1A1TSHRLMNARAB9AHSD17B10
SCHEMBL425825 0.75 FAAH (0.40) FAAH
SCHEMBL424570 0.74 FAAH (0.44) ALDH1A1TSHRLMNARAB9AHSD17B10
SCHEMBL425588 0.74 DRD2 (0.54) ALDH1A1TSHRLMNAFAAHSMN1; SMN2
SCHEMBL14938150 0.74 FAAH (0.52) ALDH1A1TSHRLMNARAB9AHSD17B10
SCHEMBL17460234 0.74 MGLL (0.60) ALDH1A1LMNAFAAHTP53MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9353082-B2 Pharmaceutical compounds BIAL—PORTELA & CA, S.A. (PT) 2016-05-31 US disclosed
US-9353082-B2 Pharmaceutical compounds BIAL—PORTELA & CA, S.A. (PT) 2016-05-31 US disclosed
US-9353082-B2 Pharmaceutical compounds BIAL—PORTELA & CA, S.A. (PT) 2016-05-31 US disclosed
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2012-03-15 US disclosed
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2012-03-15 US disclosed
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2012-03-15 US disclosed
WO-2010074588-A2 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2010-07-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS FAAH, FAAH2, ASAH1 ALDH1A1 294/4885TSHR 2673/4885LMNA 2523/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.